TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,844,681 | +6.0% | 346,068 | -0.6% | 0.02% | +26.7% |
| Q1 2024 | $2,684,082 | +35.3% | 348,130 | +57.8% | 0.02% | +15.4% |
| Q4 2023 | $1,983,600 | -33.3% | 220,645 | -33.7% | 0.01% | -40.9% |
| Q3 2023 | $2,975,706 | -5.4% | 332,853 | +62.5% | 0.02% | +4.8% |
| Q2 2023 | $3,145,459 | +271.2% | 204,782 | +443.5% | 0.02% | +320.0% |
| Q1 2023 | $847,333 | +10491.7% | 37,676 | +10948.7% | 0.01% | – |
| Q3 2022 | $8,000 | -98.1% | 341 | -98.0% | 0.00% | -100.0% |
| Q2 2022 | $421,000 | -76.0% | 17,388 | -74.5% | 0.00% | -80.0% |
| Q1 2022 | $1,755,000 | -22.1% | 68,117 | -6.1% | 0.02% | -28.6% |
| Q4 2021 | $2,252,000 | +126.8% | 72,548 | +77.2% | 0.02% | +61.5% |
| Q3 2021 | $993,000 | -38.4% | 40,932 | -63.0% | 0.01% | -27.8% |
| Q2 2021 | $1,613,000 | +224.5% | 110,575 | +456.0% | 0.02% | +200.0% |
| Q1 2021 | $497,000 | -53.4% | 19,889 | -49.2% | 0.01% | -60.0% |
| Q4 2020 | $1,067,000 | – | 39,161 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,026,300 | $21,583 | 6.98% |
| Deep Track Capital, LP | 4,582,000 | $96,359,460 | 4.05% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 379,019 | $7,963,189 | 2.46% |
| ARMISTICE CAPITAL, LLC | 6,412,000 | $134,844,360 | 2.35% |
| GREAT POINT PARTNERS LLC | 475,000 | $9,989,250 | 1.96% |
| RA Capital Management | 3,984,681 | $83,797,841 | 1.70% |
| MPM BioImpact LLC | 281,711 | $5,924,382 | 1.54% |
| HighVista Strategies LLC | 121,834 | $2,562,169 | 1.52% |
| Kynam Capital Management, LP | 418,099 | $8,792,622 | 1.35% |
| SECTORAL ASSET MANAGEMENT INC | 292,320 | $6,147,490 | 1.19% |